Correlation Between Acrivon Therapeutics, and Inhibrx

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Inhibrx, you can compare the effects of market volatilities on Acrivon Therapeutics, and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Inhibrx.

Diversification Opportunities for Acrivon Therapeutics, and Inhibrx

0.64

Correlation Coefficient

Acrivon Therapeutics,  Inhibrx

Poor diversification

The 3 months correlation between Acrivon and Inhibrx is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Inhibrx go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Inhibrx

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to generate 1.4 times more return on investment than Inhibrx. However, Acrivon Therapeutics, is 1.4 times more volatile than Inhibrx. It trades about 0.0 of its potential returns per unit of risk. Inhibrx is currently generating about -0.1 per unit of risk. If you would invest  759.00  in Acrivon Therapeutics, Common on September 19, 2024 and sell it today you would lose (38.00) from holding Acrivon Therapeutics, Common or give up 5.01% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Inhibrx

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Acrivon Therapeutics, is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Inhibrx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Acrivon Therapeutics, and Inhibrx

The main advantage of trading using opposite Acrivon Therapeutics, and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.

The idea behind Acrivon Therapeutics, Common and Inhibrx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.